No differences in efficacy and safety were seen in a study cohort of 1325 patients undergoing frontline treatment with lenvatinib for unresectable hepatocellular carcinoma.
No differences in efficacy and safety were observed in a study cohort of 1325 patients undergoing frontline treatment with lenvatinib (Lenvima) for unresectable hepatocellular carcinoma (HCC). Patients were stratified by age with patients older than 80 vs patients 80 years and younger by survival outcomes, disease control rate, and response rate. Findings were presented at the European Association for the Study of the Liver (EASL): Liver Cancer Summit 2024.1
Median overall survival (OS) was 15.7 months for patients older than 80 years vs patients 80 years and younger, respectively (HR, 1.02; 95% CI, 0.84-1.25; P = .8281), Andrea Casadei Gardini, MD, and coinvestigators presented in a poster during the conference.1
Median progression-free survival (PFS) was 6.3 months for patients older than 80 years vs patients 80 years and younger, respectively (HR, 1.07; 95% CI, 0.91-1.25; P = .3954). No differences between the 2 study groups were found in terms of disease control rate (80.8% vs 78.8%; P = .44) and response rate (38.2% vs 37.9%; P = 0.88).1 Data evaluating the use of lenvatinib in very elderly patients are limited, although the incidence of HCC in this patient population is constantly increasing.1 Prior to the current study, a trial evaluated 100 patients with HCC who received lenvatinib were selected using propensity score matching.2 Regarding OS and PFS, there were no significant differences between the elderly and nonelderly groups (HR, 0.972; 95% CI, 0.374-2.529; and HR, 1.362; 95% CI, 0.687-2.700, respectively).2 Tada T, et al reported that elderly patients experienced fatigue (36.0%), decreased appetite (26.0%), and hypothyroidism (24.0%).2
In the current study, investigators reported that patients younger than 80 years experienced significantly more hand-foot skin reactions (grade ≥ 2) and decrease appetite (grade ≥ 2) than patients 80 years and older. Patients 80 years and older experienced significantly more fatigue (grade ≥ 2).1 Researchers noted that Barcelona Clinic Liver Cancer stage was the only independent predictor of OS (HR, 1.59; 95% CI, 1.11-2.29; P = .01115).1
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More